Pharming Capex To Operating Cash Flow from 2010 to 2024

PHAR Stock  USD 9.27  0.53  6.06%   
Pharming Group Capex To Operating Cash Flow yearly trend continues to be relatively stable with very little volatility. Capex To Operating Cash Flow is likely to grow to -0.08 this year. During the period from 2010 to 2024, Pharming Group Capex To Operating Cash Flow destribution of quarterly values had r-value of  0.37 from its regression line and median of (0.03). View All Fundamentals
 
Capex To Operating Cash Flow  
First Reported
2010-12-31
Previous Quarter
(0.08)
Current Value
(0.08)
Quarterly Volatility
0.17015227
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.7 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 6.5 M, as well as many indicators such as Price To Sales Ratio of 3.62, Dividend Yield of 0.0 or PTB Ratio of 3.92. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Check out the analysis of Pharming Group Correlation against competitors.

Latest Pharming Group's Capex To Operating Cash Flow Growth Pattern

Below is the plot of the Capex To Operating Cash Flow of Pharming Group NV over the last few years. It is Pharming Group's Capex To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
Capex To Operating Cash Flow10 Years Trend
Slightly volatile
   Capex To Operating Cash Flow   
       Timeline  

Pharming Capex To Operating Cash Flow Regression Statistics

Arithmetic Mean0.05
Coefficient Of Variation361.88
Mean Deviation0.14
Median(0.03)
Standard Deviation0.17
Sample Variance0.03
Range0.5931
R-Value0.37
Mean Square Error0.03
R-Squared0.14
Significance0.17
Slope0.01
Total Sum of Squares0.41

Pharming Capex To Operating Cash Flow History

2024 -0.0804
2023 -0.0846
2022 0.0863
2021 0.44
2020 0.18
2019 0.34
2018 0.0933

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as Capex To Operating Cash Flow, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capex To Operating Cash Flow(0.08)(0.08)

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.